

新潟脳神経研究会特別例会の御案内

日 時: <u>令和7年8月5日(火) 16:00~17:00(JST)</u> 開催方法:ハイブリッド開催 <u>会 場 脳研究所 遺伝子機能解析学分野 検討会室</u> Zoom ミーティングID :914 2582 3987 パスコード :896831

## THE APOE ε4 GENE AT THE CROSSROADS OF NEURODEGENERATION: DEFINING ITS ROLE IN PARKINSON'S DISEASE ONSET AND PROGRESSION — TOWARDS PRECISION NEUROLOGY



## Gita Vita Soraya, MD, Ph.D<sup>1,2,3</sup>

Associate Professor

<sup>1</sup>Department of Neurology, Faculty of Medicine, Hasanuddin University <sup>2</sup>Department of Biochemistry and Molecular Biology, Faculty of Medicine, Hasanuddin University <sup>3</sup>Neurology Division, Hasanuddin University Hospital (脳研究所共同研究拠点国際共同研究者)

Parkinson's disease (PD), the most prevalent movement disorder, remains a major global burden. While the Apolipoprotein E (APOE) gene is well known for its involvement in Alzheimer's disease and other neurodegenerative conditions, its role in PD has remained elusive, with conflicting evidence across studies. This study explored the impact of the APOE  $\varepsilon$ 4 allele in Indonesian PD patients and complemented the findings with a global meta-analysis. Genetic analysis revealed that 2 out of 3 PD patients in the cohort carried the APOE  $\varepsilon$ 4 allele. A meta-analysis of 14 published studies (up to January 2025) confirmed a significantly earlier age of onset in  $\varepsilon$ 4 carriers (SMD = -0.16, 95% CI: -0.24 to -0.08, p = 0.0001). In contrast, no significant differences were observed in disease severity (Hoehn and Yahr stage) or cognitive performance (MIMSE) between  $\varepsilon$ 4 carriers and non-carriers. These results suggest that APOE  $\varepsilon$ 4 functions as a genetic modifier, accelerating PD onset without markedly affecting clinical progression or cognition. Understanding its role may help identify high-risk individuals and contribute to the development of precision neurology approaches in PD care. I look forward to sharing these insights and engaging in discussion with all of you.

どうぞ奮ってご参加ください。

(担当:脳研究所 遺伝子機能解析学分野)

